Cipla Ltd  has received tentative approval from the U.S. Food and Drug Administration for cetirizine hydrochloride tablets

Cipla Ltd has received tentative approval from the U.S. Food and Drug Administration for cetirizine hydrochloride tablets. Cetirizine is an antihistamine. Cetirizine blocks the actions of the naturally occurring chemical histamine in the body. Cetirizine is less likely than some other antihistamines to cause side effects such as drowsiness and dizziness. The drug treats symptoms associated with seasonal allergic rhinitis.

The Company's principal activity is to manufacture chemicals and pharmaceutical products. The products of the Company include anti-asthmatics, anti-cancer, anti-inflammatory, anti-depressant and other therapeutic index including animal health care products. The Company also provides technology services for preparation of product, product and process know how and new developments. Its manufacturing facilities are located in Maharashtra, Karnataka, Goa and Himachal Pradesh. The products of the Company are sold in India, Africa, Middle East, Europe, America, Asia and Australia.